NYSE:BDX - Becton Dickinson and Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$233.20 +3.08 (+1.34 %)
(As of 06/21/2018 12:08 PM ET)
Previous Close$232.97
Today's Range$231.11 - $235.26
52-Week Range$191.53 - $248.39
Volume32,545 shs
Average Volume1.10 million shs
Market Capitalization$61.46 billion
P/E Ratio24.71
Dividend Yield1.30%
Beta1.12
Becton Dickinson and logoBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BDX
CUSIP07588710
Phone201-847-6800

Debt

Debt-to-Equity Ratio1.07
Current Ratio1.70
Quick Ratio1.12

Price-To-Earnings

Trailing P/E Ratio24.71
Forward P/E Ratio21.22
P/E Growth1.6

Sales & Book Value

Annual Sales$12.09 billion
Price / Sales5.15
Cash Flow$14.2980 per share
Price / Cash16.31
Book Value$56.89 per share
Price / Book4.10

Profitability

EPS (Most Recent Fiscal Year)$9.48
Net Income$1.10 billion
Net Margins-0.46%
Return on Equity14.27%
Return on Assets5.24%

Miscellaneous

Employees41,933
Outstanding Shares267,200,000

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and announced a quarterly dividend on Monday, April 23rd. Stockholders of record on Friday, June 8th will be paid a dividend of $0.75 per share on Friday, June 29th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Thursday, June 7th. View Becton Dickinson and's Dividend History.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) posted its quarterly earnings data on Thursday, May, 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.63 by $0.02. The medical instruments supplier had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The business's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period last year, the business posted $2.30 EPS. View Becton Dickinson and's Earnings History.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Becton Dickinson and.

What guidance has Becton Dickinson and issued on next quarter's earnings?

Becton Dickinson and updated its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $10.90-$11.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $15.84-$15.90, compared to the consensus revenue estimate of $15.85 billion.

What price target have analysts set for BDX?

16 equities research analysts have issued 12-month price objectives for Becton Dickinson and's stock. Their predictions range from $175.00 to $260.00. On average, they anticipate Becton Dickinson and's share price to reach $235.9375 in the next year. View Analyst Ratings for Becton Dickinson and.

Who are some of Becton Dickinson and's key competitors?

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the folowing people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 65)
  • Mr. Thomas E. Polen Jr., Pres (Age 45)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 61)
  • Mr. Alexandre Conroy, Pres of Worldwide Medication & Procedural Solutions (Age 55)
  • Dr. Ellen R. Strahlman, Former Exec. VP of R&D and Chief Medical Officer (Age 61)

Has Becton Dickinson and been receiving favorable news coverage?

Media stories about BDX stock have been trending somewhat positive recently, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Becton Dickinson and earned a daily sentiment score of 0.10 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 47.05 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.09%), JPMorgan Chase & Co. (1.71%), Franklin Resources Inc. (1.40%), Wells Fargo & Company MN (1.35%), Northern Trust Corp (1.24%) and Fiera Capital Corp (1.03%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, David F Melcher, Ellen R Strahlman, Gary M Cohen, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Institutional Ownership Trends for Becton Dickinson and.

Which major investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Coho Partners Ltd., Westwood Holdings Group Inc., Sei Investments Co., Robeco Institutional Asset Management B.V., Guggenheim Capital LLC, Findlay Park Partners LLP and Hsbc Holdings PLC. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Ellen R Strahlman, Gary M Cohen, James W Borzi, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Insider Buying and Selling for Becton Dickinson and.

Which major investors are buying Becton Dickinson and stock?

BDX stock was purchased by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Rockefeller Capital Management L.P., The Manufacturers Life Insurance Company, CI Investments Inc., Northern Trust Corp, Summit Trail Advisors LLC, Russell Investments Group Ltd. and Winslow Capital Management LLC. View Insider Buying and Selling for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $233.20.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $61.46 billion and generates $12.09 billion in revenue each year. The medical instruments supplier earns $1.10 billion in net income (profit) each year or $9.48 on an earnings per share basis. Becton Dickinson and employs 41,933 workers across the globe.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.


MarketBeat Community Rating for Becton Dickinson and (BDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  447 (Vote Underperform)
Total Votes:  798
MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.